title: Activated T cells armed with bispecific antibodies kill tumor targets.
abstract: OBJECTIVE
  Adoptive T-cell therapy has become one of the most exciting fields of cancer therapy in the past few years. In this article, we describe a method which combines adoptive T-cell therapy with antibody therapy by arming T cells from cord blood, normal patients, and cancer patients with bispecific antibodies capable of binding to tumor-associated antigens on one side of the bispecific antibody construct and T cells on another side of the construct. This approach redirects T cells against tumor cells in a non-MHC-restricted manner.
  
  
  RESULTS
  Various methods for manipulating the immune system including check-point inhibitors, chimeric antigen receptor T cells, and bispecific antibodies have shown promising activity in treating both hematological malignancies and solid tumors with excellent success. In recent studies, activated T cells armed with bispecific antibodies have shown good preclinical activity, safety, and promising efficacy in the clinical trials.
  
  
  CONCLUSIONS
  Activated T cells armed with bispecific antibodies represent a promising treatment for cancer immunotherapy.
authors.affiliation: aDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA bDepartment of Immunology and Microbiology, Wayne State University and Barbara Ann Karmanos Cancer Center, Detroit, Michigan, USA.
authors.forename: Divaya
authors.initials: D
authors.lastname: Bhutani
authors.forename: Lawrence G
authors.initials: LG
authors.lastname: Lum
mesh_terms: D018033:Antibodies, Bispecific / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*
chemical_list: D018033:Antibodies, Bispecific